HYPERION DEFI, INC. Deferred Federal Income Tax Expense (Benefit)
HYPERION DEFI, INC. (HYPD) reported Deferred Federal Income Tax Expense (Benefit) of $9.09 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-03-30
- HYPERION DEFI, INC. deferred federal income tax expense (benefit) for fiscal 2025 was $9.09M, a 28.68% decline from fiscal 2024.
- HYPERION DEFI, INC. deferred federal income tax expense (benefit) for fiscal 2024 was $12.75M, a 136.90% increase from fiscal 2023.
- HYPERION DEFI, INC. deferred federal income tax expense (benefit) for fiscal 2023 was $5.38M, a 8.46% decline from fiscal 2022.
- HYPERION DEFI, INC. deferred federal income tax expense (benefit) for fiscal 2022 was $5.88M.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month | Deferred Federal Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | $9.09M 10-K · filed 2026-03-30 | |
| 2024-12-31 | $12.75M 10-K · filed 2026-03-30 | |
| 2023-12-31 | $5.38M 10-K · filed 2025-04-15 | |
| 2022-12-31 | $5.88M 10-K · filed 2024-03-18 | |
| 2021-12-31 | -$1.25M 10-K · filed 2023-03-31 | |
| 2020-12-31 | -$3.80M 10-K · filed 2022-03-30 | |
| 2019-12-31 | -$5.00M 10-K · filed 2021-03-30 | |
| 2018-12-31 | -$3.52M 10-K · filed 2020-03-30 | $3.52M 10-K · filed 2019-03-27 |
| 2017-12-31 | $235.47K 10-K · filed 2019-03-27 | |
| 2016-12-31 | $1.29M 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |